Type 2 diabetes Nutritional, Metabolic, Endocrine Non-insulin-dependent diabetes mellitus
Conditions
Interventions
Drugs/placebo administered in Study A and B:
A/B 1: one placebo tablet (oral) stat dose
A/B 2: 1 g metformin (oral) stat dose
A/B 3: 120 mg nateglinide (oral) stat dose
In Study A and B all subj
this time they were kept fasting. In Study A subjects were not on any oral hypoglycaemic agents. In Study B if any of the subjects were on an oral hypoglycaemic agent this was stopped for a 3-week was
Sponsors
Royal Victoria Hospital (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Both males and females, aged greater than 18 years 2. Type 2 diabetes controlled by diet or a single oral hypoglycaemic agent 3. HbA1c less than 7.5% 4. No significant liver, cardiac or renal problems (creatinine greater than 150 mmol/l)
Exclusion criteria
Exclusion criteria: Type 2 diabetes on two or more hypoglycaemic agents or requiring insulin.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood samples were collected from the participants at -5, 0, 30, 60, 120, 180 and 240 minutes for the measurements of the following: 1. Glucose 2. Insulin 3. C-peptide 4. DPPIV activity 5. GLP-1 | — |
Secondary
| Measure | Time frame |
|---|---|
| Serum metformin levels, measured by high performance liquid chromatography on blood samples collected at 0, 60, 120 and 240 minutes. | — |
Countries
United Kingdom
Outcome results
None listed